GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: JEDI-1444 is from a series of antibacterial compounds that target UDP-2,3-diacylglucosamine hydrolase (LpxH), an essential enzyme in the lipopolysaccharide synthesis pathway, that is conserved in the majority of Gram-negative bacteria but absent in human [1]. JEDI-1444 was identified as part of a programme to develop LpxH inhibitors with activity against efflux-proficient Gram-negative bacteria. It was designed by combining structural elements from existing LpxH inhibitors AZ1 and JEDI-852 and was subsequently used to derive improved analogues EBL-3599 and EBL-3647.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 2-[methyl(methylsulfonyl)amino]-N-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]sulfonylphenyl]benzamide |
Database Links ![]() |
|
| Specialist databases | |
Antibiotic DB
|
JEDI-1444 |
| Other databases | |
| CAS Registry No. | 2851905-89-8 (source: Scifinder) |
| PubChem CID | 166075264 |
| RCSB PDB Ligand | VQ9 |
| Search Google for chemical match using the InChIKey | JURGWQSEARSCQN-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | JURGWQSEARSCQN |
| UniChem Compound Search for chemical match using the InChIKey | JURGWQSEARSCQN-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | JURGWQSEARSCQN-UHFFFAOYSA-N |